MedTrace Logo

Special Survey for Long Term Application

NCT01516229 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 395

Last updated 2017-02-27

No results posted yet for this study

Summary

This study is conducted in Japan. The aim of this study is to assess the incidence rate of adverse drug reactions (ADRs) when using somatropin (Norditropin®) for treatment of for achondroplasia without epiphyseal line closure under normal clinical practice conditions.

Conditions

Interventions

DRUG

somatropin

Prescription of somatropin at the discretion of the physician

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Min Age
1 Year
Max Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-05-01
Primary Completion
2007-03-31
Completion
2007-03-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01516229 on ClinicalTrials.gov